ORAL COMMUNICATION | Semaglutide plus empagliflozin improves renal outcomes compared with monotherapies in type 2 diabetes: a real-world study. Italian Journal of Medicine, [S. l.], v. 20, n. s1, 2026. DOI: 10.4081/itjm.2026.2593. Disponível em: https://www.italjmed.org/ijm/article/view/2593. Acesso em: 22 jul. 2026.